US9750438B2 - CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery - Google Patents
CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery Download PDFInfo
- Publication number
- US9750438B2 US9750438B2 US14/015,831 US201314015831A US9750438B2 US 9750438 B2 US9750438 B2 US 9750438B2 US 201314015831 A US201314015831 A US 201314015831A US 9750438 B2 US9750438 B2 US 9750438B2
- Authority
- US
- United States
- Prior art keywords
- hypoglycemia
- insulin
- risk
- subject
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G06F19/3437—
-
- G06F19/3456—
-
- G06F19/3468—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G06F19/3418—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Definitions
- Some aspects of some embodiments of this invention are in the field of medical methods, systems, and computer program products related to managing the treatment of diabetic subjects, more particularly to glycemic analysis and control. Some embodiments of the invention relate to means for preventing hypoglycemia in a subject with diabetes.
- CGM continuous glucose monitor
- Insulin pump shut-off algorithms use CGM data to inform the decision to completely stop the flow of insulin based on a prediction of hypoglycaemia. This approach has been shown to reduce the risk of nocturnal hypoglycaemia.
- a possible drawback is that the use of an on-off control law for basal insulin, similar to bang-bang or relay control, may induce undesired oscillations of plasma glucose. In fact, if the basal insulin is higher than that needed to keep the glycemic target, the recovery from hypoglycemia would be followed by application of the basal that will cause a new shut-off occurrence. The cycle of shut-off interventions yields an insulin square wave that induces periodic oscillation of plasma glucose.
- An aspect of an embodiment of the present invention seeks to, among other things, remedy the problems in the prior art.
- CGM subcutaneous continuous glucose monitoring
- CPHS Hypoglycemia System
- An aspect of an embodiment of the present invention CGM-Based Prevention of Hypoglycemia System (CPHS) and related method disclosed here serves to, but not limited thereto, provide an independent mechanism for mitigating the risk of hypoglycemia.
- Applications of this technology include, but not limited thereto, CGM-informed conventional insulin pump therapy, CGM-informed open-loop control systems, and closed-loop control systems. These systems may be most applicable to the treatment of Type 1 and Type 2 diabetes (T1DM and T2DM, respectively), but other applications are possible.
- An aspect of an embodiment or partial embodiment of the present invention comprises, but is not limited to, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment.
- a further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia.
- the two outputs of the CPHS can be used in combination or individually.
- An aspect of an embodiment of the present invention innovates in numerous ways on existing technologies by acting on the risk of hypoglycemia and not explicitly and exclusively on the glucose level.
- An aspect of an embodiment of the invention further innovates by gradually decreasing insulin levels, therefore avoiding under-insulinization of the patient and reducing the risk of hyperglycemia as compared to rigid pump shut-off algorithms.
- An aspect of an embodiment of the invention also uses insulin pump feedback to increase the accuracy of the hypoglycemia risk assessment.
- An aspect of an embodiment of the invention further integrates an alert system that not only informs the user that the system is actively preventing hypoglycemia but is also capable of requesting user intervention in case no amount of insulin.
- An aspect of an embodiment of the CPHS prevents hypoglycemia, rather than merely manipulating BG into a specific target or tight range.
- An aspect of an embodiment of the present invention provides a method for preventing or mitigating hypoglycemia in a subject.
- the method may comprise the following: obtaining metabolic measurements associated with the subject; continuously assessing a risk of hypoglycemia based on the metabolic measurements; and evaluating the risk of hypoglycemia to determine one of the following outcomes 1) no action is needed, 2) attenuation of insulin delivery is needed, 3) additional intervention is needed, or 3) attenuation of insulin delivery and additional intervention are needed.
- An aspect of an embodiment of the present invention provides a system for preventing or mitigating hypoglycemia in a subject.
- the system may comprise the following: an obtaining device for obtaining metabolic measurements associated with the subject; an assessment device for continuously assessing a risk of hypoglycemia based on the metabolic measurements; and an evaluation device for evaluating the risk of hypoglycemia to determine one of the following outcomes: 1) no action is needed, 2) attenuation of insulin delivery is needed, 3) additional intervention is needed, or 4) attenuation of insulin delivery and additional intervention are needed.
- An aspect of an embodiment of the present invention provides a computer program product comprising a computer useable medium having a computer program logic for enabling at least one processor in a computer system to prevent or mitigate hypoglycemia in a subject.
- the computer logic may comprise the following: obtaining data of metabolic measurements associated with the subject; continuously assessing a risk of hypoglycemia based on the metabolic measurements; and evaluating the risk of hypoglycemia to determine one of the following outcomes: 1) no action is needed, 2) attenuation of insulin delivery is needed 3) additional intervention is needed, or 4) attenuation of insulin delivery and additional intervention are needed.
- the continuous assessment may occur X times per second, where 1 ⁇ X ⁇ 1000 (as well as at a faster rate or frequency if desired or required). It should be appreciated that the continuous assessment may occur X times per hour, where 1 ⁇ X ⁇ 1000. It should be appreciated that the continuous assessment may occur X times per day, where 1 ⁇ X ⁇ 1000. The assessment can be made periodically or at time intervals where their duration and frequency can vary. As an example, the assessment may occur every minute or every few to several minutes.
- Another example of continuous assessment shall include any point in time where a sample (for example, but not limited thereto, BG, CGM samples, glucose measurements, etc.) or input (for example, but not limited thereto, basal rate change, bolus events acknowledged by the pump, etc.) is received that can be assessed.
- a sample for example, but not limited thereto, BG, CGM samples, glucose measurements, etc.
- input for example, but not limited thereto, basal rate change, bolus events acknowledged by the pump, etc.
- the risk assessment may be event driven.
- a given day(s) can be skipped for conducting assessment activities or steps.
- FIG. 1 schematically provides an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIG. 2 schematically provides an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIG. 3 schematically provides a more detailed exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS) from FIG. 2 .
- CPHS hypoglycemia system
- FIG. 4 schematically provides an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIG. 5 schematically provides an exemplary embodiment of the CGM-based prevention of hypoglycemia method (and modules of a related system).
- FIGS. 6A and 6B schematically provide simulation results from an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIGS. 7A and 7B schematically provide simulation results from an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIG. 8 schematically provides simulation results from an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIGS. 9A and 9B schematically provide simulation results from an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIG. 10 schematically provides simulation results from an exemplary embodiment of the CGM-based prevention of hypoglycemia system (CPHS).
- CPHS hypoglycemia system
- FIG. 11 provides a schematic block diagram of an aspect of an embodiment of the present invention relating processors, communications links, and systems, for example.
- FIG. 12 Provides a schematic block diagram of an aspect of an embodiment of the present invention relating processors, communications links, and systems, for example.
- FIG. 13 Provides a schematic block diagram of an aspect of an embodiment of the present invention relating processors, communications links, and systems, for example.
- FIG. 14 Provides a schematic block diagram for an aspect of a system or related method of an aspect of an embodiment of the present invention.
- An aspect of an embodiment of the CGM-Based Prevention of Hypoglycemia System (CPHS) (and related method and computer program product) presented here may utilize CGM data to continually assess the risk of hypoglycemia for the patient and then provides two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia.
- the two outputs of the CPHS can be used in combination or individually.
- the first section below presents the CPHS for the case where the only input to the system is CGM data.
- the second section presents the CPHS for the case where, in addition to CGM data, the system receives as an input some external data, including insulin commands.
- a distinguishing aspect of an embodiment of the present invention system, method and computer program product compared to other methods of hypoglycemia prevention, for example, but not limited thereto is its use of formal assessments of hypoglycemia risk, both in determining the appropriate attenuation of insulin and in producing the appropriate red/yellow/green signal.
- Another aspect of an embodiment of the present invention is the attenuation function of the CPHS (and related method and computer program product), which adjusts the restriction of insulin as a smooth function of CGM measures, not abruptly, as in prior art pump-shutoff methods.
- CPHS and related method and computer program product
- a specific methodology based on a risk symmetrization function is presented.
- the same techniques could be used for other risk assessment techniques, including risk assessments that use other input signals such as meal acknowledgement information and indications of physical activity, as long as they vary smoothly as a function of CGM data.
- No other hypoglycemia prevention system relies on the use of risk assessments to produce a smoothly varying attenuation factor.
- Another aspect of an embodiment of the present invention system, method and computer program product is the traffic signal abstraction for the hypoglycemia alarm system.
- This section presents a basic form of an embodiment of the present invention in which only CGM data is used to prevent hypoglycemia, as illustrated in FIG. 1 . It should be noted that the CPHS can function without any other input signals. This subsection explains how the CPHS would operate in a CGM-only configuration. Also included is an illustration of procedures by which the attenuation factor is computed and red/yellow/green light hypoglycemia alarms are generated (See FIG. 2 ).
- FIG. 1 illustrates a first exemplary embodiment of the hypoglycemia prevention system 100 .
- the subject such as a patient 102 may be a diabetic subject who takes insulin to prevent complications arising from diabetes.
- Continuous Glucose Monitor (CGM) 104 collects information about the patient, specifically blood or interstitial glucose levels. The blood or interstitial glucose data is measured directly from the patient 102 , without the inclusion of any intermediary or independent device.
- CPHS 106 takes as input the blood glucose data acquired by CGM 104 . Based on this data, the CPHS 106 evaluates the risk of hypoglycemia. The risk corresponds to one or more actions to be taken, including taking no action, attenuating insulin delivery, and/or taking additional intervention.
- a subject may be a human or any animal. It should be appreciated that an animal may be a variety of any applicable type, including, but not limited thereto, mammal, veterinarian animal, livestock animal or pet type animal, etc. As an example, the animal may be a laboratory animal specifically selected to have certain characteristics similar to human (e.g. rat, dog, pig, monkey), etc. It should be appreciated that the subject may be any applicable human patient, for example.
- FIG. 2 illustrates a second exemplary embodiment of the hypoglycemia prevention system 200 .
- a subject such as a patient 202 is a diabetic subject and the CGM 204 collects information about the patient 202 .
- the CPHS 206 takes as input the blood glucose data acquired by CGM 204 . Based on this data, the CPHS 206 evaluates the risk of hypoglycemia and determines whether and what kind of action to take. These actions include taking no action, attenuating insulin delivery, and/or taking additional intervention.
- a visual indicator 210 displays a colored light.
- the CPHS 206 will take no action and the visual indicator 210 will present a green light (or other type of indicator as desired or required). If the risk of hypoglycemia is low the CPHS 206 will attenuate insulin delivery and the visual indicator 210 will present a yellow light (or other type of indicator as desired or required). If the risk of hypoglycemia is high, the CPHS 206 will either (1) call for additional intervention, or (2) call for additional intervention and attenuate insulin delivery. In either case, the visual indicator, will present a red light (or other type of indicator as desired or required).
- any of the embodiments discussed herein may be intended for some sort or kind of visual tracking.
- information that is conveyed visually may be conveyed audibly and/or tactically (perceptible to the sense of touch) if desired or required.
- a audible and/or tactile scheme would be provided to convey or provide at least some or all of the aspects being conveyed visually or in combination therewith.
- audible signals may be provided in addition to or in concert or parallel with the visual information.
- FIG. 3 presents a more detailed view of the system illustrated in FIG. 2 .
- the subject or patient CGM 304 , and insulin delivery device 306 are provided.
- the CPHS 308 uses CGM data, y(t), to compute an attenuation factor, ⁇ brakes (R(t), based on a risk of hypoglycemia assessment, R(t).
- the CPHS 308 may also or solely present to the user red, yellow, or green lights indicating the risk of hypoglycemia via visual indicator 310 .
- the CPHS is designed to add a safety supervision function to different types of blood glucose management functions, including conventional therapy, open-loop and advisory mode systems, and closed loop systems.
- the CPHS 306 serves to modify insulin rates by modifying the programmed rate of insulin injection, J command (t), J in the insulin delivery device 308 .
- the attenuation factor output of the CGM-only CPHS is computed via an algorithmic process referred to as brakes.
- the brakes algorithm and method are designed to adjust insulin rate commands to the insulin pump to avoid hypoglycemia.
- a feature of an embodiment of the present invention is that brake action smoothly attenuates the patient's insulin delivery rate at the present time t by monitoring CGM and insulin pump data, assessing a measure of the patient's future risk of hypoglycemia R(t), and then computing an attenuation factor ⁇ brakes (R(t)).
- the attenuation factor is computed as follows:
- ⁇ brakes ⁇ ( R ⁇ ( t ) ) 1 1 + k ⁇ R ⁇ ( t ) where k is an aggressiveness parameter that may be adjusted to match the patient's physiology (i.e. according to the patient's insulin sensitivity).
- J actual (t) is the attenuated insulin rate (U/hr) and J command (t) is the rate of insulin injection (U/hr) that the pump is set to administer.
- the risk assessment function R(t) is computed purely from CGM data, as follows. First, R(t) is computed as a sample average of raw risk values:
- M is the size of the moving average window for risk assessment and, for any stage t, the raw risk value is computed as
- R ⁇ ⁇ ( t ) ⁇ 10 ⁇ [ ⁇ ⁇ ( ⁇ ) ⁇ ( ln ⁇ ( y ⁇ ( t ) ) ⁇ ⁇ ( ⁇ ) - ⁇ ⁇ ( ⁇ ) ) ] 2 if ⁇ ⁇ 20 ⁇ y ⁇ ( t ) ⁇ ⁇ 100 if ⁇ ⁇ y ⁇ ( t ) ⁇ 20 0 otherwise .
- y(t) (mg/dl) is either the most recent CGM sample or an average of recent CGM samples (e.g.
- ⁇ is the glucose concentration below which the risk function will be positive, resulting in an attenuation factor ⁇ brakes (R(t)) ⁇ 1.
- FIG. 6(A) involves 100 in silico patients with T1DM, using the UVA and U.
- the experiment is designed to reflect the situation where a patient's insulin sensitivity is greatly enhanced, say due exercise. Note that 46% of the patients experience blood glucose below 60 (mg/dl), and 88% of the patients experience blood glucose below 70 (mg/dl).
- the chart demonstrates the minimum and maximum BG over the duration of the experiment plotted on the on the X- and Y-axis, respectively, and the graph indicates the BG (mg/dl) over time (hours).
- FIG. 6(B) presents the simulation with an elevated basal rate with CGM-only brakes.
- the chart demonstrates the minimum and maximum BG over the duration of the experiment plotted on the on the X- and Y-axis, respectively, and the graph indicates the BG (mg/dl) over time (hours).
- the CPHS (and related method and computer program product) employs a new hypoglycemia alarm that provides a color-coded signal to the patient based on the abstraction of a traffic light.
- a new hypoglycemia alarm that provides a color-coded signal to the patient based on the abstraction of a traffic light.
- K red also depends upon the embodiment of the system. If 60 mg/dl is acknowledged as the onset of hypoglycemia, then K red could be chosen as 65 mg/dl, so that the patient has the opportunity to administer rescue carbohydrates before the hypoglycemic threshold is crossed. To avoid false alarms, it might be desirable as an alternative to require y(t) ⁇ K red for a specified amount of time (e.g. two minutes) before tripping the red light.
- FIG. 5 illustrates an exemplary embodiment of the CGM-based prevention of hypoglycemia method and system.
- step 502 obtains metabolic measurements from the subject.
- step 504 includes continuously assessing the risk of hypoglycemia.
- step 506 includes evaluating the risk of hypoglycemia to determines what possible action to take.
- Possible actions may include step 508 - 1 , taking no action; step 508 - 2 , attenuating insulin delivery; step 508 - 3 , taking additional intervention; and step 508 - 4 , attenuating insulin delivery and taking additional intervention.
- Insulin pump data refers either to (1) commands from the user (in conventional therapy) or controller (in open- or closed-loop control) or (2) feedback from the pump regarding delivered insulin (regardless of the type of control employed).
- the method described here also extends to configurations where, in addition to CGM and insulin pump data, yet other inputs are available to the CPHS, including meal information, indications of physical activity, and heart rate information.
- the insulin pump data or other external input data are indirect metabolic measurements. These measurements are not collected directly from the patient and are collected from other sources that can indicate information about the current patient state. For instance, insulin pump data is an indirect metabolic measurement.
- an embodiment of the CPHS disclosed can take as inputs both direct metabolic measurements and indirect metabolic measurements. This general situation is depicted in FIG. 4 .
- the outputs of the system 400 are: (1) an attenuation factor designed to restrict the delivery of insulin when there is significant risk of hypoglycemia and (2) a red/yellow/green light alarm system to inform the user of impending hypoglycemia.
- FIG. 4 presents an illustration of an enhanced hypoglycemia prevention system 400 including a CPHS, which uses CGM data and insulin pump data (associated with either conventional therapy or open or closed loop control systems) to (1) compute an attenuation factor based on an assessment of the risk of hypoglycemia and/or (2) present to the user red, yellow, or green lights indicating the risk of hypoglycemia.
- the subject or patient, 402 is a diabetic subject and the CGM 404 collects information about the patient.
- the CPHS 406 takes as input the blood glucose data acquired by the CGM 404 . Based on this data, the CPHS 406 evaluates the risk of hypoglycemia and determines whether and what kind of action to take.
- the visual indicator 410 displays a colored light (or other indicator as desired or required). As in the previous embodiments, if there is no risk of hypoglycemia, the CPHS 406 will take no action and the visual indicator 410 will present a green light. If the risk of hypoglycemia is low the CPHS 406 will attenuate insulin delivery, and the visual indicator 410 will present a yellow light. If the risk of hypoglycemia is high, the CPHS 406 , will either (1) call for additional intervention, or (2) call for additional intervention and attenuate insulin delivery. In either case, the visual indicator 410 will present a red light.
- an embodiment of the invention can correct the glucose signal used in the risk calculation.
- the focus is on the case where, in addition to CGM data and possibly other signals, the CPHS has explicit access to insulin pump data coming either in the form of (1) user inputs (i.e. commanded insulin rate at any time and insulin boluses whenever they occur) or (2) feedback from the pump regarding delivered insulin.
- the system is generic in that requests for insulin may come either from conventional therapy (with the patient in charge) or from open- or closed-loop control.
- the corrected glucose reading y corrected (t) is used to compute a corrected raw assessment of the risk of hypoglycemia ⁇ tilde over (R) ⁇ corrected (t), as below:
- R corrected ⁇ ( t ) ⁇ 10 ⁇ [ ⁇ ⁇ ( ⁇ ) ⁇ ( ln ⁇ ( y corrected ⁇ ( t ) ) ⁇ ⁇ ( ⁇ ) - ⁇ ⁇ ( ⁇ ) ) ] 2 if ⁇ ⁇ 20 ⁇ y corrected ⁇ ( t ) ⁇ ⁇ 100 if ⁇ ⁇ y corrected ⁇ ( t ) ⁇ 20 0 otherwise .
- the parameters ⁇ ( ⁇ ), ⁇ ( ⁇ ), and ⁇ ( ⁇ ) are computed in advanced based on a threshold glucose concentration ⁇ (mg/dl), which is specific to the embodiment of the CPHS.
- the corrected assessment of risk R corrected (t) is used to compute a power brakes pump attenuation factor ⁇ powerbrakes (R corrected (t)), as follows:
- the power brakes algorithm is designed to smoothly adjust insulin rate commands to the insulin pump to avoid hypoglycemia.
- the parameters k, M, and ⁇ will be manually set to other fixed values in concert with the patient's physician (e.g. according to the patient's insulin sensitivity and eating behavior) or input by the patient or other individual providing the input.
- the parameters k, M, and ⁇ will be set according to regression formulas involving the patient's physical characteristics (e.g. body weight, total daily insulin TDI (U), carbohydrate ratio, correction factor CF (mg/dl/U), age, etc.).
- the first method of computing corrected glucose involves the use of a metabolic state observer, which in turn (1) requires a model of blood glucose-insulin dynamics and (2) requires knowledge of insulin pump commands and ingested carbohydrates.
- x(t) denotes a vector of metabolic states associated with the patient, representing things like interstitial glucose concentration, plasma glucose concentration, insulin concentrations, contents of the gut, etc.
- An important benefit of an embodiment of the power brakes is that as soon as anticipated blood glucose reaches 110 mg/dl the attenuation-affect is release (sooner than would be the case with just brakes).
- ⁇ can be allowed to vary. For example, if the patient is unwilling unable to provide detailed information about meal content (making it difficult to predict future blood sugar), it may be desirable to adjust ⁇ in the time frame after meals, as follows:
- ⁇ ⁇ 0 , if ⁇ ⁇ t - t meal ⁇ 60 , 30 , otherwise , where t meal represents the time of the most recent meal.
- the second method of computing y corrected (t) involves the use of the patient's correction factor CF (used in computing appropriate correction boluses in conventional therapy) and requires knowledge of the amount of active correction insulin i correction (t) (U) in the patient's body at time t, which can be obtained from standard methods of computing insulin on board.
- A [ .9913 - 102.7 - 1.50 ⁇ 10 - 8 - 2.89 ⁇ 10 - 6 - 4.1 ⁇ 10 - 4 0 2.01 ⁇ 10 - 6 4.30 ⁇ 10 - 5 0 .839 5.23 ⁇ 10 - 10 7.44 ⁇ 10 - 8 6.84 ⁇ 10 - 6 0 0 0 0 0 0 .9798 0 0 0 0 0 0 0 .0200 .9798 0 0 0 0 0 0 0 0 0 1.9 ⁇ 10 - 4 .0180 .7882 0 0 0 .0865 - 4.667 - 2.73 ⁇ 10 - 10 - 6.59 ⁇ 10 - 8 - 1.26 ⁇ 10 - 5 .9131 6.00 ⁇ 10 - 8 1.90 ⁇ 10 - 6 0 0 0 0 0 0 .9083 0 0 0 0 0 0 0
- FIG. 6 shows that 46% of the patients experience blood glucose below 60 (mg/dl), and 88% of the patients experience blood glucose below 70 (mg/dl).
- the chart demonstrates the minimum and maximum BG over the duration of the experiment plotted on the on the X- and Y-axis, respectively, and the graph indicates the BG (mg/dl) over time (hours).
- the chart demonstrates the minimum and maximum BG over the duration of the experiment plotted on the on the X- and Y-axis, respectively, and the graph indicates the BG (mg/dl) over time (hours).
- the power brakes can act to reduce basal insulin so as to substantially reduce the incidence of hypoglycemia, as illustrated in FIGS. 8 and 9 .
- the chart demonstrates the minimum and maximum BG over the duration of the experiment plotted on the on the X- and Y-axis, respectively, and the graph indicates the BG (mg/dl) over time (hours).
- the chart demonstrates the minimum and maximum BG over the duration of the experiment plotted on the on the X- and Y-axis, respectively, and the graph indicates the BG (mg/dl) over time (hours).
- An embodiment of the CPHS (and related method and computer program product) with Insulin Input Commands uses a new hypoglycemia alarm system that provides a color-coded signal to the patient based on the abstraction of a traffic light, augmenting the hypoglycemia prevention capabilities of the power brakes themselves.
- a new hypoglycemia alarm system that provides a color-coded signal to the patient based on the abstraction of a traffic light, augmenting the hypoglycemia prevention capabilities of the power brakes themselves.
- this system will present a:
- the Red/Yellow/Green Light Hypoglycemia Alarm System uses the corrected measurement value y corrected (t) and the corrected risk function R corrected (t) as a principle means of determining what signal to present:
- y corrected,OFF (t) is an assessment of anticipated blood glucose concentration given that the insulin pump is completely shut down.
- K red also depends upon the embodiment of the system. If 60 mg/dl is acknowledged as the onset of hypoglycemia, then K red could be chosen as 65 mg/dl, so that the patient has the opportunity to administer rescue carbohydrates before the hypoglycemic threshold is crossed. To avoid false alarms, it might be desirable as an alternative to require BG off (t+ ⁇
- ⁇ in the computation of y corrected (t), the value of ⁇ is specific to the embodiment of the invention. Note that ⁇ >0 corresponds to the anticipated value of blood glucose assuming that no more insulin is delivered.
- a second method of computing y corrected,OFF (t) corresponds to second method of computing y corrected (t) described above.
- y corrected,OFF ( t ) y ( t ) ⁇ CF ⁇ i correction ( t ) where y(t) is the most recent CGM sample (or moving average of recent CGM samples) and CF and i correction (t) are as they were above.
- FIG. 10 shows results from the UVA/U.
- Padova Metabolic Simulator for 100 adult Type 1 in silico patients, with basal rates of insulin delivery set to be twice their fasting levels. With elevated basal rates, all 100 patients eventually become hypoglycemic (by crossing 60 (mg/dl)). Note that on average the yellow light turns on 118 minutes before hypoglycemia and the red light turns on 34 minutes before hypoglycemia.
- the plot shows the transition from green to yellow to red for a representative subject. The plot demonstrates BG, mg/dl, on the Y-axis and time, minutes, on the X-axis.
- FIGS. 11-13 show block diagrammatic representations of aspects of exemplary embodiments of the present invention.
- a block diagrammatic representation of the system 1110 essentially comprises the glucose meter 1128 used by a patient 1112 for recording, inter alia, insulin dosage readings and measured blood glucose (“BG”) levels.
- Data obtained by the glucose meter 1128 is preferably transferred through appropriate communication links 1114 or data modem 1132 to a processor, processing station or chip 1140 , such as a personal computer, PDA, netbook, laptop, or cellular telephone, or via appropriate Internet portal.
- a processor, processing station or chip 1140 such as a personal computer, PDA, netbook, laptop, or cellular telephone, or via appropriate Internet portal.
- glucose meter 1128 may be directly downloaded into the personal computer or processor 1140 (or PDA, netbook, laptop, etc.) through an appropriate interface cable and then transmitted via the Internet to a processing location.
- the communication link 1114 may be hardwired or wireless. Examples of hardwired may include, but not limited thereto, cable, wire, fiber optic, and/or telephone wire. Examples of wireless may include, but not limited thereto, Bluetooth, cellular phone link, RF link, and/or infrared link.
- 11-13 may be transmitted to the appropriate or desired computer networks ( 1152 , 1252 , 1352 ) in various locations and sites.
- the modules and components of FIG. 11 may be transmitted to the appropriate or desired computer networks 1152 in various locations and sites (local and/or remote) via desired or required communication links 1114 .
- an ancillary or intervention device(s) or system(s) 1154 may be in communication with the patient as well as the glucose meter and any of the other modules and components shown in FIG. 11 .
- ancillary device(s) and system(s) may include, but not necessarily limited thereto, any combination of one or more of the following: insulin pump, artificial pancreas, insulin device, pulse oximetry sensor, blood pressure sensor, ICP sensor, EMG sensor, EKG sensor, ECG sensor, ECC sensor, pace maker, and heart rate sensor, needle, ultrasound device, or subcutaneous device (as well as any other biometric sensor or device).
- insulin pump artificial pancreas
- insulin device may include, but not necessarily limited thereto, any combination of one or more of the following: insulin pump, artificial pancreas, insulin device, pulse oximetry sensor, blood pressure sensor, ICP sensor, EMG sensor, EKG sensor, ECG sensor, ECC sensor, pace maker, and heart rate sensor, needle, ultrasound device, or subcutaneous device (as well as any other biometric sensor or device).
- ICP sensor blood pressure sensor
- EMG sensor EKG sensor
- ECG sensor ECG sensor
- ECC sensor pace maker
- heart rate sensor as well as any other bio
- An indirect communication may include, but not limited thereto, a sample of blood or other biological fluids, or insulin data.
- a direct communication (which should not to be confused with a “direct measurement” as discussed and claimed herein) may include blood glucose (BG) data.
- BG blood glucose
- the glucose meter is common in the industry and includes essentially any device that can function as a BG acquisition mechanism.
- the BG meter or acquisition mechanism, device, tool or system includes various conventional methods directed towards drawing a blood sample (e.g. by fingerprick) for each test, and a determination of the glucose level using an instrument that reads glucose concentrations by electromechanical methods.
- various methods for determining the concentration of blood analytes without drawing blood have been developed.
- U.S. Pat. No. 5,267,152 to Yang et al. (hereby incorporated by reference) describes a noninvasive technique of measuring blood glucose concentration using near-IR radiation diffuse-reflection laser spectroscopy. Similar near-IR spectrometric devices are also described in U.S. Pat. No. 5,086,229 to Rosenthal et al. and U.S. Pat. No. 4,975,581 to Robinson et al. (of which are hereby incorporated by reference).
- U.S. Pat. No. 5,139,023 to Stanley describes a transdermal blood glucose monitoring apparatus that relies on a permeability enhancer (e.g., a bile salt) to facilitate transdermal movement of glucose along a concentration gradient established between interstitial fluid and a receiving medium.
- a permeability enhancer e.g., a bile salt
- U.S. Pat. No. 5,036,861 to Sembrowich (hereby incorporated by reference) describes a passive glucose monitor that collects perspiration through a skin patch, where a cholinergic agent is used to stimulate perspiration secretion from the eccrine sweat gland. Similar perspiration collection devices are described in U.S. Pat. No. 5,076,273 to Schoendorfer and U.S. Pat. No. 5,140,985 to Schroeder (of which are hereby incorporated by reference).
- U.S. Pat. No. 5,279,543 to Glikfeld (hereby incorporated by reference) describes the use of iontophoresis to noninvasively sample a substance through skin into a receptacle on the skin surface. Glikfeld teaches that this sampling procedure can be coupled with a glucose-specific biosensor or glucose-specific electrodes in order to monitor blood glucose.
- International Publication No. WO 96/00110 to Tamada (hereby incorporated by reference) describes an iotophoretic apparatus for transdermal monitoring of a target substance, wherein an iotophoretic electrode is used to move an analyte into a collection reservoir and a biosensor is used to detect the target analyte present in the reservoir.
- U.S. Pat. No. 6,144,869 to Berner (hereby incorporated by reference) describes a sampling system for measuring the concentration of an analyte present.
- the BG meter or acquisition mechanism may include indwelling catheters and subcutaneous tissue fluid sampling.
- the computer, processor or PDA 1140 may include the software and hardware necessary to process, analyze and interpret the self-recorded or automatically recorded by a clinical assistant device diabetes patient data in accordance with predefined flow sequences and generate an appropriate data interpretation output.
- the results of the data analysis and interpretation performed upon the stored patient data by the computer or processor 1140 may be displayed in the form of a paper report generated through a printer associated with the personal computer or processor 1140 .
- the results of the data interpretation procedure may be directly displayed on a video display unit associated with the computer or processor 1140 .
- the results additionally may be displayed on a digital or analog display device.
- the personal computer or processor 1140 may transfer data to a healthcare provider computer 1138 through a communication network 1136 .
- the data transferred through communications network 1136 may include the self-recorded or automated clinical assistant device diabetes patient data or the results of the data interpretation procedure.
- FIG. 12 shows a block diagrammatic representation of an alternative embodiment having a diabetes management system that is a patient-operated apparatus or clinical-operated apparatus 1210 having a housing preferably sufficiently compact to enable apparatus 1210 to be hand-held and carried by a patient.
- a strip guide for receiving a blood glucose test strip (not shown) is located on a surface of housing 1216 .
- Test strip receives a blood sample from the patient 1212 .
- the apparatus may include a microprocessor 1222 and a memory 1224 connected to microprocessor 1222 .
- Microprocessor 1222 is designed to execute a computer program stored in memory 1224 to perform the various calculations and control functions as discussed in greater detail above.
- a keypad 1216 may be connected to microprocessor 1222 through a standard keypad decoder 1226 .
- Display 1214 may be connected to microprocessor 1222 through a display driver 1230 .
- Display 1214 may be digital and/or analog.
- Speaker 1254 and a clock 1256 also may be connected to microprocessor 1222 .
- Speaker 1254 operates under the control of microprocessor 1222 to emit audible tones alerting the patient to possible future hypoglycemic or hyperglycemic risks.
- Clock 1256 supplies the current date and time to microprocessor 1222 . Any displays may be visual as well as adapted to be audible.
- Memory 1224 also stores blood glucose values of the patient 1212 , the insulin dose values, the insulin types, and the parameters used by the microprocessor 1222 to calculate future blood glucose values, supplemental insulin doses, and carbohydrate supplements. Each blood glucose value and insulin dose value may be stored in memory 1224 with a corresponding date and time. Memory 1224 is may be a non-volatile memory, such as an electrically erasable read only memory (EEPROM).
- EEPROM electrically erasable read only memory
- Apparatus 1210 may also include a blood glucose meter 1228 connected to microprocessor 1222 .
- Glucose meter 1228 may be designed to measure blood samples received on blood glucose test strips and to produce blood glucose values from measurements of the blood samples. As mentioned previously, such glucose meters are well known in the art. Glucose meter 1228 is preferably of the type which produces digital values which are output directly to microprocessor 1222 . Alternatively, blood glucose meter 1228 may be of the type which produces analog values. In this alternative embodiment, blood glucose meter 1228 is connected to microprocessor 1222 through an analog to digital converter (not shown).
- Apparatus 1210 may further include an input/output port 1234 , such as a serial port, which is connected to microprocessor 1222 .
- Port 1234 may be connected to a modem 1232 by an interface, such as a standard RS232 interface.
- Modem 1232 is for establishing a communication link 1248 between apparatus 1210 and a personal computer 1240 or a healthcare provider computer 1238 through a communication link 1248 .
- the modules and components of FIG. 12 may be transmitted to the appropriate or desired computer networks 1252 in various locations and sites (local and/or remote) via desired or required communication links 1248 .
- an ancillary or intervention device(s) or system(s) 1254 may be in communication with the patient as well as the glucose meter and any of the other modules and components shown in FIG. 12 .
- ancillary device(s) and system(s) may include, but not necessarily limited thereto any combination of one or more of the following: insulin pump, artificial pancreas, insulin device, pulse oximetry sensor, blood pressure sensor, ICP sensor, EMG sensor, EKG sensor, ECG sensor, ECC sensor, pace maker, heart rate sensor, needle, ultrasound device, or subcutaneous device (as well as any other biometric sensor or device).
- the ancillary or intervention device(s) or system(s) 1254 and glucose meter 1228 may be any sort of physiological or biological communication with the patients (i.e., subject).
- This physiological or biological communication may be direct or indirect.
- An indirect communication may include, but not limited thereto, a sample of blood or other biological fluids.
- Specific techniques for connecting electronic devices, systems and software through connections, hardwired or wireless, are well known in the art.
- Another alternative example is “Bluetooth” technology communication.
- FIG. 13 shows a block diagrammatic representation of an alternative embodiment having a diabetes management system that is a patient-operated apparatus 1310 , similar to the apparatus as shown in FIG. 12 , having a housing preferably sufficiently compact to enable the apparatus 1310 to be hand-held and carried by a patient.
- a separate or detachable glucose meter or BG acquisition mechanism/module 1328 may be transmitted to the appropriate or desired computer networks 1352 in various locations and sites (local and/or remote) via desired or required communication links 1336 .
- an ancillary or intervention device(s) or system(s) 1354 may be in communication with the patient as well as the glucose meter and any of the other modules and components shown in FIG. 13 .
- ancillary device(s) and system(s) may include, but not necessarily limited thereto any combination of one or more of the following: insulin pump, artificial pancreas, insulin device, pulse oximetry sensor, blood pressure sensor, ICP sensor, EMG sensor, EKG sensor, ECG sensor, ECC sensor, pace maker, heart rate sensor needle, ultrasound device, or subcutaneous device (as well as any other biometric sensor or device).
- the ancillary or intervention device(s) or system(s) 1354 and glucose meter 1328 may be any sort of physiological or biological communication with the patients (i.e., subject). This physiological or biological communication may be direct or indirect. An indirect communication may include, but not limited thereto, a sample of blood or other biological fluids.
- CGM devices may include: Guardian and Paradigm from Medtronic; Freestyle navigator (Abbott Diabetes Care); and Dexcom Seven from Dexcom, Inc., or other available CGM devices.
- the embodiments described herein are capable of being implemented over data communication networks such as the internet, making evaluations, estimates, and information accessible to any processor or computer at any remote location, as depicted in FIGS. 11-13 and/or U.S. Pat. No. 5,851,186 to Wood, of which is hereby incorporated by reference herein.
- patients located at remote locations may have the BG data transmitted to a central healthcare provider or residence, or a different remote location.
- any of the components/modules discussed in FIGS. 11-13 may be integrally contained within one or more housings or separated and/or duplicated in different housings. Similarly, any of the components discussed in FIGS. 11-13 may be duplicated more than once. Moreover, various components and modules may be adapted to replace another component or module to perform the intended function.
- any of the components/modules present in FIGS. 11-13 may be in direct or indirect communication with any of the other components/modules.
- the healthcare provide computer module as depicted in FIGS. 11-13 may be any location, person, staff, physician, caregiver, system, device or equipment at any healthcare provider, hospital, clinic, university, vehicle, trailer, or home, as well as any other location, premises, or organization as desired or required.
- a patient or subject may be a human or any animal.
- an animal may be a variety of any applicable type, including, but not limited thereto, mammal, veterinarian animal, livestock animal or pet type animal, etc.
- the animal may be a laboratory animal specifically selected to have certain characteristics similar to human (e.g. rat, dog, pig, monkey), etc.
- the subject may be any applicable human patient, for example.
- the patient or subject may be applicable for, but not limited thereto, any desired or required treatment, study, diagnosis, monitoring, tracking, therapy or care.
- FIG. 14 is a functional block diagram for a computer system 1400 for implementation of an exemplary embodiment or portion of an embodiment of present invention.
- a method or system of an embodiment of the present invention may be implemented using hardware, software or a combination thereof and may be implemented in one or more computer systems or other processing systems, such as personal digit assistants (PDAs), personal computer, laptop, netbook, network, or the like equipped with adequate memory and processing capabilities.
- PDAs personal digit assistants
- the invention was implemented in software running on a general purpose computer as illustrated in FIG. 14 .
- the computer system 1400 may includes one or more processors, such as processor 1404 .
- the Processor 1404 is connected to a communication infrastructure 1406 (e.g., a communications bus, cross-over bar, or network).
- the computer system 1400 may include a display interface 1402 that forwards graphics, text, and/or other data from the communication infrastructure 1406 (or from a frame buffer not shown) for display on the display unit 1430 .
- the computer system 1400 may also include a main memory 1408 , preferably random access memory (RAM), and may also include a secondary memory 1410 .
- the secondary memory 1410 may include, for example, a hard disk drive 1412 and/or a removable storage drive 1414 , representing a floppy disk drive, a magnetic tape drive, an optical disk drive, a flash memory, etc.
- the removable storage drive 1414 reads from and/or writes to a removable storage unit 1418 in a well known manner.
- Removable storage unit 1418 represents a floppy disk, magnetic tape, optical disk, etc. which is read by and written to by removable storage drive 1414 .
- the removable storage unit 1418 includes a computer usable storage medium having stored therein computer software and/or data.
- secondary memory 1410 may include other means for allowing computer programs or other instructions to be loaded into computer system 1400 .
- Such means may include, for example, a removable storage unit 1422 and an interface 1420 .
- removable storage units/interfaces include a program cartridge and cartridge interface (such as that found in video game devices), a removable memory chip (such as a ROM, PROM, EPROM or EEPROM) and associated socket, and other removable storage units 1422 and interfaces 1420 which allow software and data to be transferred from the removable storage unit 1422 to computer system 1400 .
- the computer system 1400 may also include a communications interface 1424 .
- Communications interface 1424 allows software and data to be transferred between computer system 1400 and external devices.
- Examples of communications interface 1424 may include a modem, a network interface (such as an Ethernet card), a communications port (e.g., serial or parallel, etc.), a PCMCIA slot and card, a modem, etc.
- Software and data transferred via communications interface 1424 are in the form of signals 1428 which may be electronic, electromagnetic, optical or other signals capable of being received by communications interface 1424 .
- Signals 1428 are provided to communications interface 1424 via a communications path (i.e., channel) 1426 .
- Channel 1426 (or any other communication means or channel disclosed herein) carries signals 1428 and may be implemented using wire or cable, fiber optics, blue tooth, a phone line, a cellular phone link, an RF link, an infrared link, wireless link or connection and other communications channels.
- computer program medium and “computer usable medium” are used to generally refer to media or medium such as various software, firmware, disks, drives, removable storage drive 1414 , a hard disk installed in hard disk drive 1412 , and signals 1428 .
- These computer program products (“computer program medium” and “computer usable medium”) are means for providing software to computer system 1400 .
- the computer program product may comprise a computer useable medium having computer program logic thereon.
- the invention includes such computer program products.
- the “computer program product” and “computer useable medium” may be any computer readable medium having computer logic thereon.
- Computer programs are may be stored in main memory 1408 and/or secondary memory 1410 . Computer programs may also be received via communications interface 1424 . Such computer programs, when executed, enable computer system 1400 to perform the features of the present invention as discussed herein. In particular, the computer programs, when executed, enable processor 1404 to perform the functions of the present invention. Accordingly, such computer programs represent controllers of computer system 1400 .
- the software may be stored in a computer program product and loaded into computer system 1400 using removable storage drive 1414 , hard drive 1412 or communications interface 1424 .
- the control logic when executed by the processor 1404 , causes the processor 1404 to perform the functions of the invention as described herein.
- the invention is implemented primarily in hardware using, for example, hardware components such as application specific integrated circuits (ASICs).
- ASICs application specific integrated circuits
- the invention is implemented using a combination of both hardware and software.
- the methods described above may be implemented in SPSS control language or C++ programming language, but could be implemented in other various programs, computer simulation and computer-aided design, computer simulation environment, MATLAB, or any other software platform or program, windows interface or operating system (or other operating system) or other programs known or available to those skilled in the art.
- any one or more features of any embodiment of the invention can be combined with any one or more other features of any other embodiment of the invention, without departing from the scope of the invention. Still further, it should be understood that the invention is not limited to the embodiments that have been set forth for purposes of exemplification, but is to be defined only by a fair reading of claims that are appended to the patent application, including the full range of equivalency to which each element thereof is entitled.
- any particular described or illustrated activity or element any particular sequence or such activities, any particular size, speed, material, duration, contour, dimension or frequency, or any particularly interrelationship of such elements.
- any activity can be repeated, any activity can be performed by multiple entities, and/or any element can be duplicated.
- any activity or element can be excluded, the sequence of activities can vary, and/or the interrelationship of elements can vary. It should be appreciated that aspects of the present invention may have a variety of sizes, contours, shapes, compositions and materials as desired or required.
- any activity can be repeated, any activity can be performed by multiple entities, and/or any element can be duplicated. Further, any activity or element can be excluded, the sequence of activities can vary, and/or the interrelationship of elements can vary. Unless clearly specified to the contrary, there is no requirement for any particular described or illustrated activity or element, any particular sequence or such activities, any particular size, speed, material, dimension or frequency, or any particularly interrelationship of such elements. Accordingly, the descriptions and drawings are to be regarded as illustrative in nature, and not as restrictive. Moreover, when any number or range is described herein, unless clearly stated otherwise, that number or range is approximate. When any range is described herein, unless clearly stated otherwise, that range includes all values therein and all sub ranges therein.
Abstract
Description
J actual(t)=φbrakes(R(t))·J command(t)
where k is an aggressiveness parameter that may be adjusted to match the patient's physiology (i.e. according to the patient's insulin sensitivity).
J actual(t)=φbrakes(R(t))·J command(t)
where M is the size of the moving average window for risk assessment and, for any stage t, the raw risk value is computed as
where y(t) (mg/dl) is either the most recent CGM sample or an average of recent CGM samples (e.g. moving average, exponentially weighted moving average, etc.) and the parameters α(θ), β(θ), and γ(θ) are computed in advance based on a threshold glucose concentration, θ (mg/dl), which is specific to the embodiment of the CPHS. Note that θ is the glucose concentration below which the risk function will be positive, resulting in an attenuation factor φbrakes(R(t))<1.
TABLE 1 | |||
Threshold Glucose | |||
Concentration θ (mg/dl) | α(θ) | β(θ) | γ(θ) |
90 | 0.384055 | 1.78181 | 12.2688 |
100 | 0.712949 | 2.97071 | 4.03173 |
112.5 | 1.08405 | 5.381 | 1.5088 |
120 | 1.29286 | 7.57332 | 0.918642 |
160 | 2.29837 | 41.8203 | 0.10767 |
200 | 3.24386 | 223.357 | 0.0168006 |
k=exp(−0.7672−0.0091·TDI+0.0449·CF)
-
- 1. Green light to the patient whenever there is no risk of hypoglycemia;
- 2. Yellow light to the patient whenever there is a risk of hypoglycemia but hypoglycemia is not imminent and could be handled by insulin attenuation; and
- 3. Red light to the patient whenever hypoglycemia is inevitable regardless of the attenuation of the insulin pump.
where, as before, the parameters α(θ), β(θ), and γ(θ) are computed in advanced based on a threshold glucose concentration θ (mg/dl), which is specific to the embodiment of the CPHS. Note that θ is the glucose concentration below which the risk function will be positive. Values for α(θ), β(θ), and γ(θ) are listed for different thresholds θ in Table 1. Finally, the corrected risk assessment Rcorrected(t) (not raw) is computed as
where, as before, M is the size of the moving average window for risk assessment.
where k is an aggressiveness parameter that may be adjusted to match the patient's physiology (i.e. according to the patient's insulin sensitivity). As illustrated in
J actual(t)=φpowerbrakes(R corrected(t))·J command(t)
where Jcommand(t) is the rate of insulin injection (U/hr) that the pump is set to administer, Jactual(t) is the attenuated insulin rate (U/hr). Thus, as with the brakes, the power brakes algorithm is designed to smoothly adjust insulin rate commands to the insulin pump to avoid hypoglycemia.
k=exp(−0.7672−0.0091·TDI+0.0449·CF).
x(t)=Ax(t−1)+Bu(t−1)+Gw(t−1),
where u(t) represents insulin inputs into the body and w(t) represents ingested carbohydrates. The corrected glucose reading is computed according to,
y corrected =C{circumflex over (x)} τ(t),
where C is a matrix that relates the metabolic state vector to measured glucose, τ is a nonnegative integer parameter, and
{circumflex over (x)} τ(t)=A τ {circumflex over (x)}(t)+A(τ)Bu(t)+A(τ)Gw(t)
where Aτ is the A matrix of the state space model raised to the r-th power and
where tmeal represents the time of the most recent meal.
y corrected(t)=α·(y(t)−CF·i correction(t))+(1−α)·y(t)
where α is an embodiment-specific parameter chosen in the unit interval [0, 1] and y(t) is the most recent CGM sample (or moving average of recent CGM samples).
x(t)=Ax(t−1)+Bu(t−1)+Gω(t−1)
where t is a discrete time index with the interval from t to t+1 corresponding to one minute of real time and
-
- 1. x(t)=(∂G(t) ∂X(t) ∂Isc1(t) ∂Isc2(t) ∂Ip(t) ∂Gsc(t) ∂Q1(t) ∂Q2(t))T is a vector of state variables referring to:
- a. blood glucose: ∂G(t)=G(t)−Gref, where G(t) mg/dl is blood glucose concentration at minute t and Gref=112.5 (mg/dl) is a reference value for blood glucose;
- b. remote compartment insulin action: ∂X(t)=X(t)−Xref where X(t) (min−1) represents the action of insulin in the remote compartment and Xref=0 (min−1) is a reference value;
- c. interstitial insulin, first compartment: ∂Isc1(t)=Isc1(t)−Isc1,ref, where Isc1(t) (mU) is insulin stored in the first of two interstitial compartments and Isc1,ref=1.2949×103 (mU) is a reference value;
- d. interstitial insulin, second compartment: ∂Isc2(t)=Isc2(t)−Isc2,ref, where Isc2(t) (mU) is insulin stored in the first of two interstitial compartments and Isc2,ref=1.2949×103 (mU) is a reference value;
- e. plasma insulin: ∂Ip(t)=Ip(t)−Ip,ref, where Ip(t) (mU) is plasma insulin and Ip,ref=111.2009 (mU) is a reference value;
- f. interstitial glucose concentration: ∂Gsc(t)=Gsc(t)−Gsc,ref, where Gsc(t) (mg/dl) is the concentration of glucose in interstitial fluids, and Gsc,ref=112.5 (mg/dl) is a reference value;
- g. gut compartment 1: ∂Q1(t)=Q1(t)−Q1,ref, where Q1(t) (mg) is glucose stored in the first of two gut compartments and Q1,ref=0 (mg) is a reference value; and
- h. gut compartment 2: Q2(t)=Q2(t)−Q2,ref, where Q2(t) (mg) is glucose stored in the first of two gut compartments and Q2,ref=0 (mg) is a reference value.
- 2. u(t)=Jcommand(t)−Jbasal(t) (mU/min) is the insulin differential control signal at time t, where Jcommand(t) (mU/min) is the current rate of insulin infusion and Jbasal(t) (mU/min) is the patient's normal/average basal rate at time t.
- 3. ω(t)=meal(t)−mealref(mg/min) is the ingested glucose disturbance signal at time t, where meal(t) is the rate of glucose ingestion and mealref=0 (mg/min) is a reference meal input value.
- 4. the state space matrices A, B, and G are
- 1. x(t)=(∂G(t) ∂X(t) ∂Isc1(t) ∂Isc2(t) ∂Ip(t) ∂Gsc(t) ∂Q1(t) ∂Q2(t))T is a vector of state variables referring to:
Estimates {circumflex over (x)}(t) of x(t) are computed based on knowledge of infused insulin u(t) and CGM measurements y(t) (mg/dl). The measurement signal can be modeled as follows:
y(t)−G ref =Cx(t)+v(t)
where v(t) (mg/dl) represents CGM signal noise and the state space matrix C is
C T=[1 0 0 0 0 0 0 0]
-
- 1. Green light to the patient whenever there is no risk of hypoglycemia;
- 2. Yellow light to the patient whenever there is a risk of hypoglycemia but hypoglycemia is not imminent and could be handled by insulin attenuation; and
- 3. Red light to the patient whenever hypoglycemia is inevitable regardless of the attenuation of the insulin pump.
y corrected,OFF(t)=C{circumflex over (x)} σ,OFF(t),
where σ is a nonnegative integer parameter, and
{circumflex over (x)} σ,OFF =A τ {circumflex over (x)}(t)+A(τ)Bu OFF(t)+A(τ)Gw(t)
where {circumflex over (x)}(t) is the current estimate of the patient's metabolic state and uOFF(t) is input signal corresponding to the insulin pump being completely shut down.
y corrected,OFF(t)=y(t)−CF·i correction(t)
where y(t) is the most recent CGM sample (or moving average of recent CGM samples) and CF and icorrection(t) are as they were above.
-
- 1. Red Light Alarm Parameters: Kred=80 (mg/dl) and σ=15 (minutes);
- 2. Yellow Light Alarm Parameters: θ=112.5 (mg/dl), and τ=15 (minutes); and
- 3. No pump attenuation, so that even when R(t)>0 the actual rate of insulin infusion is equal to commanded insulin.
- 1. Stephen D. Patek, Marc Breton, and Boris P. Kovatchev, “Control of Hypoglycemia via Estimation of Active Insulin, Glucose Forecasts, and Risk-Based Insulin Reduction,” Abstract in the Proceeding of the 2nd International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), Athens, Greece, Feb. 25-28, 2009.
- 2. Stephen D. Patek, Marc Breton, Colleen Hughes, and Boris P. Kovatchev, “Control of Hypoglycemia via Estimation of Active Insulin, Glucose Forecasts, and Risk-Based Insulin Reduction,” Poster presented at the 2nd International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), Athens, Greece, Feb. 25-28, 2009.
- 3. Stephen D. Patek, “Status of the Artificial Pancreas,” Keynote Presentation at the Annual Conference of the American Society for Artificial Internal Organs, Dallas, Tex., May 30, 2009.
- 4. Stephen D. Patek and Boris P. Kovatchev, “Artificial Pancreas: State of the Art, Control and Systems Engineering Challenges,” Invited Presentation to the Langer Group at MIT, Cambridge, Mass., Oct. 5, 2009.
- 5. Stephen D. Patek, Eyal Dassau, Marc Breton, Howard Zisser, Boris Kovatchev, Francis J. Doyle III, “Safety Supervision Module in Open- and Closed-Loop Control of Diabetes,” Abstract in the proceedings of the Diabetes Technology Meeting, November 2009.
- 6. Stephen D. Patek, Eyal Dassau, Marc Breton, Howard Zisser, Boris Kovatchev, Francis J. Doyle III, “Safety Supervision Module in Open- and Closed-Loop Control of Diabetes,” Poster presented at the Diabetes Technology Meeting, November 2009.
- 7. B. Buckingham, E. Cobry, P. Clinton, V. Gage, K. Caswell, E. Kunselman, F. Cameron, and H. P. Chase, “Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension,” Diabetes Technology and Therapeutics, vol. 11(2), pp. 93-97, 2009.
- 8. E. Cengiz, K. L. Swan, W. V. Tamborlane, G. M. Steil, A. T. Steffen and S. A. Weinzimer, “Is an Automatic Pump Suspension Feature Safe for Children with
Type 1 Diabetes? An Exploratory Analysis with Closed-Loop System”, Diabetes Technology & Therapeutics, 11, 4, 207-210, 2009. - 9. B. P. Kovatchev, D. J. Cox, L. A. Gonder-Frederick, and W. L. Clarke, “Symmetrization of the blood glucose measurement scale and its applications,” Diabetes Care, vol. 20, pp. 1655-1658, 1997.
- 10. PCT/US2008/082063, entitled “Model Predictive Control Based Method for Closed-Loop Control of Insulin Delivery in Diabetes Using Continuous Glucose Sensing”, filed Oct. 31, 2008.
- 11. PCT/US2008/069416, entitled “Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data”, filed Jul. 8, 2008.
- 12. PCT/US2008/067725, entitled “Method, System and Computer Simulation Environment for Testing of Monitoring and Control Strategies in Diabetes,” filed Jun. 20, 2008.
- 13. PCT/US2008/067723, entitled “LQG Artificial Pancreas Control System and Related Method”, filed on Jun. 20, 2008.
- 14. U.S. Ser. No. 12/516,044, filed May 22, 2009, entitled “Method, System, and Computer Program Product for the Detection of Physical Activity by Changes in Heart Rate, Assessment of Fast Changing Metabolic States, and Applications of Closed and Open Control Loop in Diabetes;” [
- 15. PCT/US2007/085588 not yet published filed Nov. 27, 2007, entitled “Method, System, and Computer Program Product for the Detection of Physical Activity by Changes in Heart Rate, Assessment of Fast Changing Metabolic States, and Applications of Closed and Open Control Loop in Diabetes;”
- 16. U.S. Ser. No. 11/943,226, filed Nov. 20, 2007, entitled “Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes;”
- 17. U.S. patent application Ser. No. 11/578,831, filed Oct. 18, 2006 entitled “Method, System and Computer Program Product for Evaluating the Accuracy of Blood Glucose Monitoring Sensors/Devices”.
- 18. PCT International Application Serial No. PCT/US2005/013792, filed Apr. 21, 2005, entitled “Method, System, and Computer Program Product for Evaluation of the Accuracy of Blood Glucose Monitoring Sensors/Devices;”
- 19. PCT International Application Serial No. PCT/US01/09884, filed Mar. 29, 2001, entitled “Method, System, and Computer Program Product for Evaluation of Glycemic Control in Diabetes Self-Monitoring Data;”
- 20. U.S. Pat. No. 7,025,425 B2 issued Apr. 11, 2006, entitled “Method, System, and Computer Program Product for the Evaluation of Glycemic Control in Diabetes from Self-Monitoring Data;”
- 21. U.S. patent application Ser. No. 11/305,946 filed Dec. 19, 2005 entitled “Method, System, and Computer Program Product for the Evaluation of Glycemic Control in Diabetes from Self-Monitoring Data” (Publication No. 2006/0094947);
- 22. PCT International Application Serial No. PCT/US2003/025053, filed Aug. 8, 2003, entitled “Method, System, and Computer Program Product for the Processing of Self-Monitoring Blood Glucose (SMBG) Data to Enhance Diabetic Self-Management;”
- 23. U.S. patent application Ser. No. 10/524,094 filed Feb. 9, 2005 entitled “Managing and Processing Self-Monitoring Blood Glucose” (Publication No. 2005/214892);
- 24. U.S. Ser. No. 12/065,257, filed Aug. 29, 2008, entitled “Accuracy of Continuous Glucose Sensors;”
- 25. PCT International Application Serial No PCT/US2006/033724, filed Aug. 29, 2006, entitled “Method for Improvising Accuracy of Continuous Glucose Sensors and a Continuous Glucose Sensor Using the Same;”
- 26. U.S. Ser. No. 12/159,891, filed Jul. 2, 2008, entitled “Method, System and Computer Program Product for Evaluation of Blood Glucose Variability in Diabetes from Self-Monitoring Data;”
- 27. PCT International Application No. PCT/US2007/000370, filed Jan. 5, 2007, entitled “Method, System and Computer Program Product for Evaluation of Blood Glucose Variability in Diabetes from Self-Monitoring Data;”
- 28. U.S. patent application Ser. No. 11/925,689 and PCT International Patent Application No. PCT/US2007/082744, both filed Oct. 26, 2007, entitled “For Method, System and Computer Program Product for Real-Time Detection of Sensitivity Decline in Analyte Sensors;”
- 29. U.S. Ser. No. 10/069,674, filed Feb. 22, 2002, entitled “Method and Apparatus for Predicting the Risk of Hypoglycemia;”
- 30. PCT International Application No. PCT/US00/22886, filed Aug. 21, 2000, entitled “Method and Apparatus for Predicting the Risk of Hypoglycemia;”
- 31. U.S. Pat. No. 6,923,763 B1, issued Aug. 2, 2005, entitled “Method and Apparatus for Predicting the Risk of Hypoglycemia;” and
- 32. Kovatchev B P, Straume M, Cox D J, Farhy L S. Risk analysis of blood glucose data: A quantitative approach to optimizing the control of insulin dependent diabetes. J of Theoretical Medicine, 3:1-10, 2001.
Claims (4)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/015,831 US9750438B2 (en) | 2009-02-25 | 2013-08-30 | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
US15/669,111 US10842419B2 (en) | 2009-02-25 | 2017-08-04 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US17/070,245 US11723562B2 (en) | 2009-02-25 | 2020-10-14 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US17/333,161 US20210282677A1 (en) | 2009-02-25 | 2021-05-28 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/069,551 US11751779B2 (en) | 2009-02-25 | 2022-12-21 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/323,117 US20240023837A1 (en) | 2009-02-25 | 2023-05-24 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/325,564 US20230293062A1 (en) | 2009-02-25 | 2023-05-30 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15535709P | 2009-02-25 | 2009-02-25 | |
US18248509P | 2009-05-29 | 2009-05-29 | |
US26393209P | 2009-11-24 | 2009-11-24 | |
PCT/US2010/025405 WO2010099313A1 (en) | 2009-02-25 | 2010-02-25 | Cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US201113203469A | 2011-10-03 | 2011-10-03 | |
US14/015,831 US9750438B2 (en) | 2009-02-25 | 2013-08-30 | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/025405 Continuation WO2010099313A1 (en) | 2009-02-25 | 2010-02-25 | Cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US13/203,469 Continuation US8562587B2 (en) | 2009-02-25 | 2010-02-25 | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/669,111 Continuation US10842419B2 (en) | 2009-02-25 | 2017-08-04 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
US20140046159A1 US20140046159A1 (en) | 2014-02-13 |
US9750438B2 true US9750438B2 (en) | 2017-09-05 |
Family
ID=42665902
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/203,469 Active US8562587B2 (en) | 2009-02-25 | 2010-02-25 | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
US14/015,831 Active 2031-06-02 US9750438B2 (en) | 2009-02-25 | 2013-08-30 | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
US15/669,111 Active 2030-08-06 US10842419B2 (en) | 2009-02-25 | 2017-08-04 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US17/070,245 Active 2031-05-19 US11723562B2 (en) | 2009-02-25 | 2020-10-14 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US17/333,161 Pending US20210282677A1 (en) | 2009-02-25 | 2021-05-28 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/069,551 Active US11751779B2 (en) | 2009-02-25 | 2022-12-21 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/323,117 Pending US20240023837A1 (en) | 2009-02-25 | 2023-05-24 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/325,564 Pending US20230293062A1 (en) | 2009-02-25 | 2023-05-30 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/203,469 Active US8562587B2 (en) | 2009-02-25 | 2010-02-25 | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/669,111 Active 2030-08-06 US10842419B2 (en) | 2009-02-25 | 2017-08-04 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US17/070,245 Active 2031-05-19 US11723562B2 (en) | 2009-02-25 | 2020-10-14 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US17/333,161 Pending US20210282677A1 (en) | 2009-02-25 | 2021-05-28 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/069,551 Active US11751779B2 (en) | 2009-02-25 | 2022-12-21 | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/323,117 Pending US20240023837A1 (en) | 2009-02-25 | 2023-05-24 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US18/325,564 Pending US20230293062A1 (en) | 2009-02-25 | 2023-05-30 | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
Country Status (6)
Country | Link |
---|---|
US (8) | US8562587B2 (en) |
EP (4) | EP3703066A1 (en) |
JP (1) | JP5661651B2 (en) |
CN (1) | CN102334113B (en) |
CA (1) | CA2753210C (en) |
WO (1) | WO2010099313A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10940267B2 (en) | 2019-07-16 | 2021-03-09 | Beta Bionics, Inc. | Blood glucose control system with real-time glycemic control optimization |
US11154656B2 (en) | 2019-07-16 | 2021-10-26 | Beta Bionics, Inc. | Blood glucose control system with medicament bolus recommendation |
US11183298B2 (en) | 2016-09-09 | 2021-11-23 | Dexcom, Inc. | Systems and methods for CGM-based bolus calculator for display and for provision to medicament delivery devices |
US11484652B2 (en) | 2017-08-02 | 2022-11-01 | Diabeloop | Closed-loop blood glucose control systems and methods |
US11744945B2 (en) | 2015-08-07 | 2023-09-05 | Trustees Of Boston University | Glucose control system with automatic adaptation of glucose target |
US20230293062A1 (en) * | 2009-02-25 | 2023-09-21 | University Of Virginia Patent Foundation | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US11878145B2 (en) | 2017-05-05 | 2024-01-23 | Ypsomed Ag | Closed loop control of physiological glucose |
US11901060B2 (en) | 2017-12-21 | 2024-02-13 | Ypsomed Ag | Closed loop control of physiological glucose |
US11957876B2 (en) | 2019-07-16 | 2024-04-16 | Beta Bionics, Inc. | Glucose control system with automated backup therapy protocol generation |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080172026A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having a suspension bolus |
US9123077B2 (en) | 2003-10-07 | 2015-09-01 | Hospira, Inc. | Medication management system |
US8065161B2 (en) | 2003-11-13 | 2011-11-22 | Hospira, Inc. | System for maintaining drug information and communicating with medication delivery devices |
WO2008057729A2 (en) | 2006-10-16 | 2008-05-15 | Hospira, Inc. | System and method for comparing and utilizing activity information and configuration information from mulitple device management systems |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
US9026370B2 (en) | 2007-12-18 | 2015-05-05 | Hospira, Inc. | User interface improvements for medical devices |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
US8271106B2 (en) | 2009-04-17 | 2012-09-18 | Hospira, Inc. | System and method for configuring a rule set for medical event management and responses |
EP4231307A1 (en) | 2009-05-29 | 2023-08-23 | University Of Virginia Patent Foundation | System coordinator and modular architecture for open-loop and closed-loop control of diabetes |
EP3284494A1 (en) | 2009-07-30 | 2018-02-21 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
JP2013503874A (en) * | 2009-09-01 | 2013-02-04 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | System, method and computer program product for regulation of insulin release (AID) in diabetes using a nominal open loop profile |
LT3920471T (en) | 2009-09-08 | 2024-02-26 | Abbott Diabetes Care, Inc. | Methods and articles of manufacture for hosting a safety critical application on an uncontrolled data processing device |
US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
DK2628115T3 (en) * | 2010-10-12 | 2015-08-24 | Univ California | Insulin Delivery Device |
BR112013033254A2 (en) * | 2011-06-23 | 2017-03-01 | Univ Virginia Patent Foundation | system for managing patient glycemic control and computer readable non-transient storage media |
AU2012299169B2 (en) | 2011-08-19 | 2017-08-24 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
ES2959510T3 (en) | 2011-10-21 | 2024-02-26 | Icu Medical Inc | Medical device update system |
WO2013090709A1 (en) | 2011-12-16 | 2013-06-20 | Hospira, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
DK2836943T3 (en) * | 2012-03-23 | 2020-03-23 | Dipartimento Di Ingegneria Civile E Architettura Delluniversita Degli Studi Di Pavia | PROCEDURE FOR PROVIDING AN INSULIN VALUE AND RELATED SYSTEM |
ES2741725T3 (en) | 2012-03-30 | 2020-02-12 | Icu Medical Inc | Air detection system and method to detect air in a pump of an infusion system |
KR101371705B1 (en) * | 2012-06-01 | 2014-03-12 | 한철민 | Safety control apparatus and method for medical device |
US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
US9715327B2 (en) | 2012-06-07 | 2017-07-25 | Tandem Diabetes Care, Inc. | Preventing inadvertent changes in ambulatory medical devices |
US9757510B2 (en) | 2012-06-29 | 2017-09-12 | Animas Corporation | Method and system to handle manual boluses or meal events for closed-loop controllers |
EP2879733B1 (en) | 2012-07-31 | 2019-06-05 | ICU Medical, Inc. | Patient care system for critical medications |
US20140066884A1 (en) | 2012-08-30 | 2014-03-06 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
US9662445B2 (en) | 2012-08-30 | 2017-05-30 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
CA2882300C (en) * | 2012-08-30 | 2020-12-29 | Medtronic Minimed, Inc. | Safeguarding techniques for a closed-loop insulin infusion system |
US10496797B2 (en) | 2012-08-30 | 2019-12-03 | Medtronic Minimed, Inc. | Blood glucose validation for a closed-loop operating mode of an insulin infusion system |
US10130767B2 (en) | 2012-08-30 | 2018-11-20 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
US9878096B2 (en) | 2012-08-30 | 2018-01-30 | Medtronic Minimed, Inc. | Generation of target glucose values for a closed-loop operating mode of an insulin infusion system |
US9486578B2 (en) | 2012-12-07 | 2016-11-08 | Animas Corporation | Method and system for tuning a closed-loop controller for an artificial pancreas |
US9907909B2 (en) | 2012-12-20 | 2018-03-06 | Animas Corporation | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
US9227014B2 (en) * | 2013-02-07 | 2016-01-05 | The Board Of Trustees Of The Laland Stanford Junior University | Kalman filter based on-off switch for insulin pump |
WO2014138446A1 (en) | 2013-03-06 | 2014-09-12 | Hospira,Inc. | Medical device communication method |
US10357606B2 (en) | 2013-03-13 | 2019-07-23 | Tandem Diabetes Care, Inc. | System and method for integration of insulin pumps and continuous glucose monitoring |
US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
US10016561B2 (en) | 2013-03-15 | 2018-07-10 | Tandem Diabetes Care, Inc. | Clinical variable determination |
AU2014268355B2 (en) | 2013-05-24 | 2018-06-14 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
ES2845748T3 (en) | 2013-05-29 | 2021-07-27 | Icu Medical Inc | Infusion system and method of use that prevent oversaturation of an analog-digital converter |
ES2838450T3 (en) | 2013-05-29 | 2021-07-02 | Icu Medical Inc | Infusion set that uses one or more sensors and additional information to make an air determination relative to the infusion set |
WO2015003124A2 (en) * | 2013-07-03 | 2015-01-08 | University Of Virginia Patent Foundation | Simulation of endogenous and exogenous glucose/insulin/glucagon interplay in type 1 diabetic patients |
US9561324B2 (en) | 2013-07-19 | 2017-02-07 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
CA2922425C (en) | 2013-08-30 | 2023-05-16 | Hospira, Inc. | System and method of monitoring and managing a remote infusion regimen |
WO2015035304A1 (en) | 2013-09-06 | 2015-03-12 | Tandem Diabetes Care, Inc. | System and method for mitigating risk in automated medicament dosing |
US9662436B2 (en) | 2013-09-20 | 2017-05-30 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
EP2862586B1 (en) * | 2013-10-21 | 2021-09-01 | F. Hoffmann-La Roche AG | Control unit for infusion pump units, including a controlled intervention unit |
CA2928557C (en) | 2013-10-24 | 2023-10-10 | Trustees Of Boston University | Infusion system for preventing mischanneling of multiple medicaments |
US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
AU2014353130B9 (en) | 2013-11-19 | 2019-09-05 | Icu Medical, Inc. | Infusion pump automation system and method |
US10569015B2 (en) | 2013-12-02 | 2020-02-25 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
CA2939302C (en) | 2014-02-28 | 2021-12-28 | Hospira, Inc. | Infusion system and method which utilizes dual wavelength optical air-in-line detection |
US10722650B2 (en) | 2014-03-28 | 2020-07-28 | Roche Diabetes Care, Inc. | System and method for adjusting therapy based on risk associated with a glucose state |
EP3138032A4 (en) | 2014-04-30 | 2017-12-20 | ICU Medical, Inc. | Patient care system with conditional alarm forwarding |
AU2015266706B2 (en) | 2014-05-29 | 2020-01-30 | Icu Medical, Inc. | Infusion system and pump with configurable closed loop delivery rate catch-up |
US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US9669160B2 (en) | 2014-07-30 | 2017-06-06 | Tandem Diabetes Care, Inc. | Temporary suspension for closed-loop medicament therapy |
JP2017527421A (en) | 2014-08-14 | 2017-09-21 | ユニヴァーシティー オブ ヴァージニア パテント ファンデーション | Method, system and device for continuous glucose monitoring with improved accuracy |
WO2016030836A1 (en) * | 2014-08-26 | 2016-03-03 | Debiotech S.A. | Detection of an infusion anomaly |
US9539383B2 (en) | 2014-09-15 | 2017-01-10 | Hospira, Inc. | System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein |
US9636453B2 (en) * | 2014-12-04 | 2017-05-02 | Medtronic Minimed, Inc. | Advance diagnosis of infusion device operating mode viability |
US9943645B2 (en) | 2014-12-04 | 2018-04-17 | Medtronic Minimed, Inc. | Methods for operating mode transitions and related infusion devices and systems |
US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
US9878097B2 (en) | 2015-04-29 | 2018-01-30 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
WO2016189417A1 (en) | 2015-05-26 | 2016-12-01 | Hospira, Inc. | Infusion pump system and method with multiple drug library editor source capability |
US10646650B2 (en) * | 2015-06-02 | 2020-05-12 | Illinois Institute Of Technology | Multivariable artificial pancreas method and system |
WO2016201120A1 (en) | 2015-06-09 | 2016-12-15 | University Of Virginia Patent Foundation | Insulin monitoring and delivery system and method for cgm based fault detection and mitigation via metabolic state tracking |
AU2016287372B2 (en) * | 2015-06-30 | 2021-07-01 | Koninklijke Philips N.V. | Control device for a medical aerosol delivery device |
CA2991058A1 (en) | 2015-07-08 | 2017-01-12 | Trustees Of Boston University | Infusion system and components thereof |
WO2017040927A1 (en) | 2015-09-02 | 2017-03-09 | University Of Virginia Patent Foundation | System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users |
CN108289642B (en) * | 2015-10-09 | 2021-02-23 | 迪诺威特公司 | Medical arrangement and method for determining insulin therapy related parameters, predicting glucose values and providing insulin delivery recommendations |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
AU2016385454B2 (en) | 2016-01-05 | 2021-12-16 | Bigfoot Biomedical, Inc. | Operating multi-modal medicine delivery systems |
US10449294B1 (en) | 2016-01-05 | 2019-10-22 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
CN112933333B (en) | 2016-01-14 | 2023-03-28 | 比格福特生物医药公司 | Adjusting insulin delivery rate |
BR112018015910A2 (en) | 2016-02-05 | 2018-12-26 | Animas Corporation | visualization and analysis tool for a drug delivery system |
IL261594B (en) | 2016-03-29 | 2022-08-01 | Hoffmann La Roche | Method of operating a receiver for receiving analyte data, receiver and computer program product |
US10311976B2 (en) * | 2016-04-28 | 2019-06-04 | Roche Diabetes Care, Inc. | Bolus calculator with probabilistic carbohydrate measurements |
CA3211813A1 (en) | 2016-05-02 | 2017-11-09 | Dexcom, Inc. | System and method for providing alerts optimized for a user |
EP4085944A1 (en) | 2016-05-13 | 2022-11-09 | ICU Medical, Inc. | Infusion pump system with common line auto flush |
US10332633B2 (en) * | 2016-06-01 | 2019-06-25 | Roche Diabetes Care, Inc. | Control-to-range aggressiveness |
US10297350B2 (en) * | 2016-06-01 | 2019-05-21 | Roche Diabetes Care, Inc. | Risk-based control-to-range |
AU2017277804B2 (en) | 2016-06-10 | 2022-05-26 | Icu Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
WO2018007172A1 (en) * | 2016-07-08 | 2018-01-11 | Novo Nordisk A/S | Basal titration with adaptive target glucose level |
US11574737B2 (en) | 2016-07-14 | 2023-02-07 | Icu Medical, Inc. | Multi-communication path selection and security system for a medical device |
MA46606A (en) * | 2016-10-31 | 2019-09-04 | Novo Nordisk As | SYSTEMS AND METHODS FOR ESTIMATING THE RISK OF A FUTURE HYPOGLYCEMIC EVENT |
WO2018077835A1 (en) | 2016-10-31 | 2018-05-03 | Novo Nordisk A/S | Systems and methods for estimating the risk of a future hypoglycemic event |
MX2019008110A (en) | 2017-01-06 | 2019-10-24 | Univ Boston | Infusion system and components thereof. |
US10583250B2 (en) | 2017-01-13 | 2020-03-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US10758675B2 (en) | 2017-01-13 | 2020-09-01 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
WO2018132765A1 (en) | 2017-01-13 | 2018-07-19 | Mazlish Bryan | Insulin delivery methods, systems and devices |
US10610644B2 (en) | 2017-01-13 | 2020-04-07 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
US10881792B2 (en) | 2017-01-13 | 2021-01-05 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US10500334B2 (en) | 2017-01-13 | 2019-12-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
USD853583S1 (en) | 2017-03-29 | 2019-07-09 | Becton, Dickinson And Company | Hand-held device housing |
US11497851B2 (en) | 2017-03-31 | 2022-11-15 | Lifescan Ip Holdings, Llc | Maintaining maximum dosing limits for closed loop insulin management systems |
US11147920B2 (en) | 2017-04-18 | 2021-10-19 | Lifescan Ip Holdings, Llc | Diabetes management system with automatic basal and manual bolus insulin control |
CN110741438B (en) * | 2017-06-15 | 2023-12-29 | 诺和诺德股份有限公司 | Basal titration with adaptive target glucose levels |
WO2018229209A1 (en) | 2017-06-15 | 2018-12-20 | Novo Nordisk A/S | Insulin titration algorithm based on patient profile |
US10089055B1 (en) | 2017-12-27 | 2018-10-02 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
US20190246914A1 (en) | 2018-02-09 | 2019-08-15 | Dexcom, Inc. | System and method for decision support |
US11872368B2 (en) | 2018-04-10 | 2024-01-16 | Tandem Diabetes Care, Inc. | System and method for inductively charging a medical device |
US11152109B2 (en) | 2018-07-17 | 2021-10-19 | Icu Medical, Inc. | Detecting missing messages from clinical environment |
NZ793485A (en) | 2018-07-17 | 2023-06-30 | Icu Medical Inc | Systems and methods for facilitating clinical messaging in a network environment |
EP3824386B1 (en) | 2018-07-17 | 2024-02-21 | ICU Medical, Inc. | Updating infusion pump drug libraries and operational software in a networked environment |
US10861592B2 (en) | 2018-07-17 | 2020-12-08 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
AU2019309766A1 (en) | 2018-07-26 | 2021-03-18 | Icu Medical, Inc. | Drug library management system |
CN109065176B (en) * | 2018-08-20 | 2020-11-10 | 清华-伯克利深圳学院筹备办公室 | Blood glucose prediction method, device, terminal and storage medium |
US10894126B2 (en) * | 2018-09-28 | 2021-01-19 | Medtronic Minimed, Inc. | Fluid infusion system that automatically determines and delivers a correction bolus |
EP3877984A1 (en) | 2018-11-06 | 2021-09-15 | Universita' Degli Studi Di Padova | A real-time continuous glucose monitoring based method to trigger carbohydrates assumption to prevent/mitigate hypoglycemic events |
US20200205742A1 (en) * | 2018-12-28 | 2020-07-02 | Dexcom, Inc. | Evaluation and visualization of glycemic dysfunction |
EP3999145A4 (en) | 2019-07-16 | 2023-07-12 | Beta Bionics, Inc. | Ambulatory device and components thereof |
US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
US11278661B2 (en) | 2020-03-10 | 2022-03-22 | Beta Bionics, Inc. | Infusion system and components thereof |
CN111631729B (en) * | 2020-05-14 | 2023-06-06 | 中国科学院深圳先进技术研究院 | Hypoglycemia prediction method and system based on multimode fusion |
US11911595B2 (en) | 2020-05-18 | 2024-02-27 | Tandem Diabetes Care, Inc. | Systems and methods for automated insulin delivery response to meal announcements |
WO2022020184A1 (en) | 2020-07-21 | 2022-01-27 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
CN112786193A (en) * | 2021-01-20 | 2021-05-11 | 上海市第六人民医院 | Monitoring and early warning system and method for hypoglycemia patient |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572542B1 (en) * | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
JP2003528330A (en) | 2000-03-29 | 2003-09-24 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | Method, system, and computer program product for evaluating blood glucose control of diabetes from self-monitoring data |
US6923763B1 (en) | 1999-08-23 | 2005-08-02 | University Of Virginia Patent Foundation | Method and apparatus for predicting the risk of hypoglycemia |
US20050171503A1 (en) | 2002-03-22 | 2005-08-04 | Greta Van Den Berghe | Automatic infusion system based on an adaptive patient model |
US20080154513A1 (en) | 2006-12-21 | 2008-06-26 | University Of Virginia Patent Foundation | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes |
US20080171913A1 (en) | 2004-11-15 | 2008-07-17 | Novo Nordisk A/S | Method and Apparatus for Monitoring Long Term and Short Term Effects of a Treatment |
US20080319394A1 (en) | 2007-06-11 | 2008-12-25 | Medingo, Ltd. | Portable infusion device with reduced level of operational noise |
US20100256592A1 (en) * | 2007-04-30 | 2010-10-07 | Medtronic, Inc. | Therapy adjustment |
US20100292634A1 (en) | 2006-06-19 | 2010-11-18 | Dose Safety | System, method and article for controlling the dispensing of insulin |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006989A1 (en) | 1988-01-29 | 1989-08-10 | The Regents Of The University Of California | Iontophoretic non-invasive sampling or delivery device |
US5076273A (en) | 1988-09-08 | 1991-12-31 | Sudor Partners | Method and apparatus for determination of chemical species in body fluid |
US5086229A (en) | 1989-01-19 | 1992-02-04 | Futrex, Inc. | Non-invasive measurement of blood glucose |
US5139023A (en) | 1989-06-02 | 1992-08-18 | Theratech Inc. | Apparatus and method for noninvasive blood glucose monitoring |
US4975581A (en) | 1989-06-21 | 1990-12-04 | University Of New Mexico | Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids |
CA2028261C (en) | 1989-10-28 | 1995-01-17 | Won Suck Yang | Non-invasive method and apparatus for measuring blood glucose concentration |
US5140985A (en) | 1989-12-11 | 1992-08-25 | Schroeder Jon M | Noninvasive blood glucose measuring device |
US5036861A (en) | 1990-01-11 | 1991-08-06 | Sembrowich Walter L | Method and apparatus for non-invasively monitoring plasma glucose levels |
JP3328290B2 (en) | 1994-06-24 | 2002-09-24 | シグナス, インコーポレイテッド | Ion introduction sampling apparatus and method |
US5851186A (en) | 1996-02-27 | 1998-12-22 | Atl Ultrasound, Inc. | Ultrasonic diagnostic imaging system with universal access to diagnostic information and images |
US6175752B1 (en) * | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
PT1077634E (en) | 1998-05-13 | 2003-12-31 | Cygnus Therapeutic Systems | MONITORING OF PHYSIOLOGICAL SUBSTANCES TO BE ANALYZED |
JPH11330283A (en) | 1998-05-15 | 1999-11-30 | Toshiba Corp | Semiconductor module and large semiconductor module |
TW571287B (en) | 2001-02-20 | 2004-01-11 | Au Optronics Corp | Display with dot inversion or column inversion and having power-saving function |
US6887271B2 (en) | 2001-09-28 | 2005-05-03 | Ethicon, Inc. | Expanding ligament graft fixation system and method |
US8010174B2 (en) * | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
EP2327359B1 (en) | 2002-08-13 | 2015-01-21 | University Of Virginia Patent Foundation | Method, system, and computer program product for processing of self-monitoring blood glucose (smbg) data to enhance diabetic self-management |
EP1575656B1 (en) * | 2002-10-11 | 2009-06-17 | Becton, Dickinson and Company | Insulin delivery system with sensor |
US20100145262A1 (en) * | 2007-05-03 | 2010-06-10 | Novo Nordisk A/S | Safety system for insulin delivery advisory algorithms |
JP2010531707A (en) * | 2007-06-25 | 2010-09-30 | メディンゴ・リミテッド | Adapted basal insulin delivery system |
US8361823B2 (en) | 2007-06-29 | 2013-01-29 | Eastman Kodak Company | Light-emitting nanocomposite particles |
JP5661651B2 (en) | 2009-02-25 | 2015-01-28 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | Prevention of hypoglycemia based on CGM by assessing risk of hypoglycemia and reducing gentle insulin release |
US10069674B2 (en) | 2013-12-12 | 2018-09-04 | International Business Machines Corporation | Monitoring file system operations between a client computer and a file server |
DE102017202499A1 (en) | 2017-02-16 | 2018-08-16 | Airbus Operations Gmbh | Communication system, aerospace vehicle and communication method |
-
2010
- 2010-02-25 JP JP2011551322A patent/JP5661651B2/en active Active
- 2010-02-25 WO PCT/US2010/025405 patent/WO2010099313A1/en active Application Filing
- 2010-02-25 CA CA2753210A patent/CA2753210C/en active Active
- 2010-02-25 EP EP20157783.0A patent/EP3703066A1/en active Pending
- 2010-02-25 US US13/203,469 patent/US8562587B2/en active Active
- 2010-02-25 EP EP10746831.6A patent/EP2399205B1/en active Active
- 2010-02-25 EP EP21213253.4A patent/EP4043878A1/en active Pending
- 2010-02-25 CN CN201080009444.1A patent/CN102334113B/en active Active
- 2010-02-25 EP EP23179361.3A patent/EP4243032A3/en active Pending
-
2013
- 2013-08-30 US US14/015,831 patent/US9750438B2/en active Active
-
2017
- 2017-08-04 US US15/669,111 patent/US10842419B2/en active Active
-
2020
- 2020-10-14 US US17/070,245 patent/US11723562B2/en active Active
-
2021
- 2021-05-28 US US17/333,161 patent/US20210282677A1/en active Pending
-
2022
- 2022-12-21 US US18/069,551 patent/US11751779B2/en active Active
-
2023
- 2023-05-24 US US18/323,117 patent/US20240023837A1/en active Pending
- 2023-05-30 US US18/325,564 patent/US20230293062A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6923763B1 (en) | 1999-08-23 | 2005-08-02 | University Of Virginia Patent Foundation | Method and apparatus for predicting the risk of hypoglycemia |
US6572542B1 (en) * | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
JP2003528330A (en) | 2000-03-29 | 2003-09-24 | ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン | Method, system, and computer program product for evaluating blood glucose control of diabetes from self-monitoring data |
US7025425B2 (en) | 2000-03-29 | 2006-04-11 | University Of Virginia Patent Foundation | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data |
US20050171503A1 (en) | 2002-03-22 | 2005-08-04 | Greta Van Den Berghe | Automatic infusion system based on an adaptive patient model |
US20080171913A1 (en) | 2004-11-15 | 2008-07-17 | Novo Nordisk A/S | Method and Apparatus for Monitoring Long Term and Short Term Effects of a Treatment |
US20100292634A1 (en) | 2006-06-19 | 2010-11-18 | Dose Safety | System, method and article for controlling the dispensing of insulin |
US20080154513A1 (en) | 2006-12-21 | 2008-06-26 | University Of Virginia Patent Foundation | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes |
JP2008194452A (en) | 2006-12-21 | 2008-08-28 | Univ Of Virginia Patent Foundation | System, method and computer program code for recognition of pattern of hyperglycemia and hypoglycemia, increased glucose variability, and ineffective self-monitoring in diabetes |
US20100256592A1 (en) * | 2007-04-30 | 2010-10-07 | Medtronic, Inc. | Therapy adjustment |
US20080319394A1 (en) | 2007-06-11 | 2008-12-25 | Medingo, Ltd. | Portable infusion device with reduced level of operational noise |
Non-Patent Citations (3)
Title |
---|
Bruce Buckingham et al: "Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension", Diabetes Technology & Therapeutics, vol. 11, No. 2, Feb. 1, 2009, pp. 93-97, ISSN: 1520-9156, DOI: 10.1089/dia.2008.0032. |
Kovatchev et al., "Assessment of Risk for Severe Hypoglycemia Among Adults with IDDM," Diabetes Care, 21:1870-1875, 1998. |
The extended European Search Report dated Sep. 16, 2013. |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230293062A1 (en) * | 2009-02-25 | 2023-09-21 | University Of Virginia Patent Foundation | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery |
US11744945B2 (en) | 2015-08-07 | 2023-09-05 | Trustees Of Boston University | Glucose control system with automatic adaptation of glucose target |
US11515036B2 (en) | 2016-09-09 | 2022-11-29 | Dexcom, Inc. | Systems and methods for CGM-based bolus calculator for display and for provision to medicament delivery devices |
US11183298B2 (en) | 2016-09-09 | 2021-11-23 | Dexcom, Inc. | Systems and methods for CGM-based bolus calculator for display and for provision to medicament delivery devices |
US11222724B2 (en) | 2016-09-09 | 2022-01-11 | Dexcom, Inc. | Systems and methods for CGM-based bolus calculator for display and for provision to medicament delivery devices |
US11456073B2 (en) | 2016-09-09 | 2022-09-27 | Dexcom, Inc. | Systems and methods for CGM-based bolus calculator for display and for provision to medicament delivery devices |
US11878145B2 (en) | 2017-05-05 | 2024-01-23 | Ypsomed Ag | Closed loop control of physiological glucose |
US11484652B2 (en) | 2017-08-02 | 2022-11-01 | Diabeloop | Closed-loop blood glucose control systems and methods |
US11901060B2 (en) | 2017-12-21 | 2024-02-13 | Ypsomed Ag | Closed loop control of physiological glucose |
US11116902B2 (en) | 2019-07-16 | 2021-09-14 | Beta Bionics, Inc. | Blood glucose control system with control parameter modification |
US11744947B2 (en) | 2019-07-16 | 2023-09-05 | Beta Bionics, Inc. | Glucose control system with control parameter modification |
US10960137B2 (en) | 2019-07-16 | 2021-03-30 | Beta Bionics, Inc. | Blood glucose control system with automated backup therapy protocol generation |
US11766518B2 (en) | 2019-07-16 | 2023-09-26 | Beta Bionics, Inc. | Glucose level control system with control parameter modification |
US11154656B2 (en) | 2019-07-16 | 2021-10-26 | Beta Bionics, Inc. | Blood glucose control system with medicament bolus recommendation |
US10940267B2 (en) | 2019-07-16 | 2021-03-09 | Beta Bionics, Inc. | Blood glucose control system with real-time glycemic control optimization |
US11941392B2 (en) | 2019-07-16 | 2024-03-26 | Beta Bionics, Inc. | Ambulatory medical device with malfunction alert prioritization |
US11957876B2 (en) | 2019-07-16 | 2024-04-16 | Beta Bionics, Inc. | Glucose control system with automated backup therapy protocol generation |
Also Published As
Publication number | Publication date |
---|---|
EP3703066A1 (en) | 2020-09-02 |
WO2010099313A1 (en) | 2010-09-02 |
CN102334113A (en) | 2012-01-25 |
US20170337348A1 (en) | 2017-11-23 |
US20140046159A1 (en) | 2014-02-13 |
EP4243032A2 (en) | 2023-09-13 |
US10842419B2 (en) | 2020-11-24 |
US20230293062A1 (en) | 2023-09-21 |
EP2399205A4 (en) | 2013-10-16 |
EP2399205B1 (en) | 2020-04-08 |
CA2753210C (en) | 2018-09-25 |
EP4043878A1 (en) | 2022-08-17 |
JP2012518498A (en) | 2012-08-16 |
US20230125221A1 (en) | 2023-04-27 |
US20120059353A1 (en) | 2012-03-08 |
CA2753210A1 (en) | 2010-09-02 |
US11723562B2 (en) | 2023-08-15 |
JP5661651B2 (en) | 2015-01-28 |
US8562587B2 (en) | 2013-10-22 |
EP2399205A1 (en) | 2011-12-28 |
US11751779B2 (en) | 2023-09-12 |
US20210282677A1 (en) | 2021-09-16 |
US20240023837A1 (en) | 2024-01-25 |
US20210038132A1 (en) | 2021-02-11 |
CN102334113B (en) | 2016-01-13 |
EP4243032A3 (en) | 2023-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11751779B2 (en) | Method, system and computer program product for CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery | |
American Diabetes Association | 7. Diabetes technology: standards of medical care in diabetes—2021 | |
KR101183854B1 (en) | Patient information input interface for a therapy system | |
US9317657B2 (en) | Method, system, and computer program product for tracking of blood glucose variability in diabetes | |
US9782076B2 (en) | Smart messages and alerts for an infusion delivery and management system | |
CA2615575C (en) | Systems, methods and computer program products for recognition of patterns of hyperglycemia in a user | |
US20200023126A1 (en) | System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users | |
US20110098548A1 (en) | Methods for modeling insulin therapy requirements | |
US20120245556A1 (en) | System, Method and Computer Program Product For Adjustment of Insulin Delivery in Diabetes Using Nominal Open-Loop Profiles | |
US20100057043A1 (en) | Method, System, and Computer Program Product for the Detection of Physical Activity by Changes in Heart Rate, Assessment of Fast Changing Metabolic States, and Applications of Closed and Open Control Loop in Diabetes | |
Kim et al. | Continuous glucose monitoring: current clinical use | |
Bhat et al. | Automated glucose control: A review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: UNIVERSITY OF VIRGINIA, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOVATCHEV, BORIS P;BRETON, MARC D;PATEK, STEPHEN D;SIGNING DATES FROM 20100414 TO 20100512;REEL/FRAME:043903/0906 Owner name: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF VIRGINIA;REEL/FRAME:043904/0097 Effective date: 20100624 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |